pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Skyrizi
drug
save

risankizumab

Marketedupdated 6mo ago
by $ABBV AbbVie Inc.
Approved
annual revenue · 2024–2024peak $11.7B
2024: $11.7B2024$11.7B
community read0 votes

🐶 often sniffed alongside

top 3
  • drugSKYRIZI92 co-mentions · 23 sources
  • tagApproval92 co-mentions · 23 sources
  • company$ABBVAbbVie Inc.46 co-mentions · 23 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.

indications

investigational
IBD (Crohn's + UC)

all catalysts(23)

approval · 23
Apr 23, 2019
approval
$ABBV294.55-0.16%
8y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 20, 2020
approval
$ABBV294.55-0.16%
7y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 26, 2021
approval
$ABBV294.55-0.16%
6y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 26, 2021
approval
$ABBV294.55-0.16%
6y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 21, 2022
approval
$ABBV294.55-0.16%
5y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 16, 2022
approval
$ABBV294.55-0.16%
4y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 16, 2022
approval
$ABBV294.55-0.16%
4y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 23, 2022
approval
$ABBV294.55-0.16%
4y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 23, 2022
approval
$ABBV294.55-0.16%
4y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 3, 2024
approval
$ABBV294.55-0.16%
3y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 3, 2024
approval
$ABBV294.55-0.16%
3y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 4, 2024
approval
$ABBV294.55-0.16%
3y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 4, 2024
approval
$ABBV294.55-0.16%
3y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 18, 2024
approval
$ABBV294.55-0.16%
2y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 18, 2024
approval
$ABBV294.55-0.16%
2y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
May 7, 2025
approval
$ABBV294.55-0.16%
2y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
May 7, 2025
approval
$ABBV294.55-0.16%
2y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 3, 2025
approval
$ABBV294.55-0.16%
1y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 3, 2025
approval
$ABBV294.55-0.16%
1y ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 6, 2026
approval
$ABBV294.55-0.16%
9mo ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 6, 2026
approval
$ABBV294.55-0.16%
9mo ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 18, 2026
approval
$ABBV294.55-0.16%
8mo ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 18, 2026
approval
$ABBV294.55-0.16%
8mo ago
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
view all 23 catalysts →

Trials studying risankizumab

  • phase4Risankizumab for Refractory Perianal Fistulizing Crohn's Diseaserecruitingn=25
  • phase3A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitisrecruitingn=120
  • phase3A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Diseaserecruitingn=110
  • phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Responseactive not recruitingn=600
  • phase2Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitisrecruitingn=2,000
  • phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritiscompletedn=553
  • phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumabrecruitingn=40
  • —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Studyactive not recruitingn=300

News(10)

  • J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
    A Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…
    biospace · 7d ago
  • AbbVie bets up to $1.47B for Nxera’s discarded IBD program
    AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
    biospace · 12d ago
  • AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
    AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
    fiercebiotech · 13d ago
  • AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
    Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
    biospace · 17d ago
  • Another autoimmune CAR-T death; Treasury zeroes in on China deals
    A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
    biopharma_dive · 21d ago
  • As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
    AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…
    biospace · 28d ago
  • AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
    AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is coden…
    endpoints · 28d ago
  • AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
    AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial.
    fiercebiotech · 29d ago
  • Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
    It’s been a busy morning for Paragon Labs. In addition to bringing over much of the leadership team from AbbVie-acquired Apogee Therapeutics, Paragon has overseen a reverse merger to take its hyper…
    fiercebiotech · 1mo ago
  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
view all news mentions →
brand
Skyrizi
generic
risankizumab-rzaa
MOA
12.1 Mechanism of Action Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.
indication
Psoriatic Arthritis
phase
marketed
approved
2019-04-23
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?